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ABSTRACT
The overlap of morphology and immunophenotype between 
angioimmunoblastic T-cell lymphoma (AITL) and other nodal peripheral T-cell 
lymphomas (n-PTCLs) is a matter of current interest whose clinical relevance and 
pathogenic background have not been fully established. We studied a series of 98 
n-PTCL samples (comprising 57 AITL and 41 PTCL-NOS) with five TFH antibodies 
(CD10, BCL-6, PD-1, CXCL13, ICOS), looked for mutations in five of the genes most 
frequently mutated in AITL (TET2, DNMT3A, IDH2, RHOA and PLCG1) using the 
Next-Generation-Sequencing Ion Torrent platform, and measured the correlations 
of these characteristics with morphology and clinical features. The percentage of 
mutations in the RHOA and TET2 genes was similar (23.5% of cases). PLCG1 was 
mutated in 14.3%, IDH2 in 11.2% and DNMT3A in 7.1% of cases, respectively. In 
the complete series, mutations in RHOA gene were associated with the presence 
of mutations in IDH2, TET2 and DNMT3A (p < 0.001, p = 0.043, and p = 0.029, 
respectively). Fourteen cases featured RHOA mutations without TET2 mutations. 
A close relationship was found between the presence of these mutations and a 
TFH-phenotype in AITL and PTCL-NOS patients. Interestingly, BCL-6 expression 
was the only TFH marker differentially expressed between AITL and PTCL-NOS 
cases. There were many fewer mutated cases than there were cases with a TFH 
phenotype. Overall, these data suggest alternative ways by which neoplastic 
T-cells overexpress these proteins. On the other hand, no clinical or survival 
differences were found between any of the recognized subgroups of patients with 
respect to their immunohistochemistry or mutational profile.
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INTRODUCTION
Peripheral T-cell lymphomas (PTCLs) are a 
heterogeneous group of non-Hodgkin lymphomas (NHLs), 
characterized by their striking clinical and biological 
heterogeneity and non-specific therapeutic regimens. In 
our field, nodal PTCLs (n-PTCLs) are the most frequently 
diagnosed, and these may be classified into three 
subgroups: angioimmunoblastic T-cell lymphoma (AITL), 
peripheral T-cell lymphoma without specific features 
(PTCL-NOS), and ALK-positive and ALK-negative 
anaplastic large T-cell lymphoma (ALCL). Diagnostic 
criteria to distinguish between AITL and PTCL-NOS are 
mainly based on morphological examination, although an 
intermediate category has been recognized (PTCL-NOS 
with TFH markers) [1]. Gene expression array studies 
indicated that AITL samples were significantly enriched 
in genes up-regulated in TFH cells [2–4]. Furthermore, 
the molecular signature of CD30-negative PTCL-NOS 
partially overlapped with that of TFH cells, although 
the correlation was not as strong as that with AITLs 
[2], suggesting that the AITL spectrum may be wider 
than suspected, as a subset of CD30(-) PTCL-NOs may 
derive from, or be related to, AITL [2]. We and other 
researchers have shown that there is also overlap between 
AITL and some PTCL-NOSs at the morphological and 
immunohistochemical profile levels [2–4]. Recently, it has 
been shown that some of these PTCL cases also share most 
of the molecular background described in AITL samples 
[2, 4–7]. Tumors that share the TFH immunophenotype 
(more than two TFH markers) are recognized as the PTCL 
with TFH phenotype and occupy a distinct provisional 
category in the new WHO classification [1]. Nevertheless, 
the criteria for identifying these patients and their clinical 
characteristics are not currently fully defined. We have 
studied a series of 98 n-PTCLs samples (comprising 57 
AITL and 41 PTCL-NOS cases) with five TFH antibodies 
(CD10, BCL-6, PD-1, CXCL13, ICOS), and looked for 
mutations in five of the genes most frequently mutated 
in AITL (TET2, DNMT3A, IDH2, RHOA, PLCG1) using 
the NGS Ion Torrent platform. We have examined the 
associations of these characteristics with morphological 
and clinical features. We found a tendency for mutated 
genes and TFH markers to cluster independently and with 
each other. Although more frequently found in the AITL 
patients, a cluster of cases carrying mutated genes and TFH 




According to the revised version of the WHO 
classification of lymphoid tumors, the TFH phenotype is 
defined as the expression of two or more (ideally, three) 
TFH-related proteins. However, neither the specific markers 
nor the intensity and percentage of positive cells have 
been defined precisely. Accordingly, 89.7% (61/68) of our 
cases had a TFH phenotype when only 10% of tumoral cells 
(defined as atypical T-cells) expressed at least two of the 
markers studied (TFH-1 group). When the cut-off value for 
the presence of positive cells for each marker was set at 
50% for each marker 51.5% (35/68) of cases were of the 
TFH phenotype (TFH-2 group). The presence of TFH markers 
occurred at a higher frequency in AITL than PTCL-NOS 
cases (Supplementary Table 1) (p = 0.068 with two or 
more markers; p = 0.059 with three or more markers). On 
the basis of clusters 1 and 2 (Figures 1 and 2) a 10% cut-
off value was chosen for use in the subsequent study. 
The most frequently found positive TFH marker 
was CXCL13, which was positive in 72.94% (62/85) of 
cases, followed by PD-1 (71.42%, 45/63 cases), BCL-6 
(64.63%, 53/82 cases), ICOS (50.63%, 40/79 cases) and 
CD10 (10.39%, 8/77).
The percentage of positive markers in the AITL 
group was 77.5% (31/40) for PD-1, 76.9% (40/52) for 
BCL-6, 73.6% (39/53) for CXCL13, 56.3% (27/48) for 
ICOS and 14.9% (7/47) for CD10. In analyzing the PTCL-
NOS group, the highest frequency of staining was seen in 
CXCL13 (71.9%, 23/32), followed by PD-1 (60.9%; 14/23), 
BCL-6 (43.3%; 13/30), ICOS (41.9%, 13/31) and CD10 
(3.3%; 1/30). BCL-6 was the only marker differentially 
expressed between the two subgroups, whereby there 
was a significantly higher level of expression in the AITL 
subgroup (p = 0.002) (Supplementary Table 2). Double 
immunohistochemistry for BCL-6/PD-1 was performed 
on TMA sections. Thirty-two of 79 valuable cases (40.5%) 
expressed both markers, being more frequent in the AITL 
subgroup of tumors (p = 0.038) (Supplementary Table 2 
and Supplementary Figure 1).
Four AITL cases (7%) showed no TFH markers 
(Supplementary Table 1).
Mutational study
An equal percentage of cases (23.5%) exhibited 
mutations in the RHOA and TET2 genes. PLCG1, IDH2 and 
DNMT3A were mutated in 14.3% (14/98), 11.2% (11/98) 
and 7.1% (7/98) of the cases (Supplementary Table 3).
The percentage of mutations varied between the 
tumors subgroups. In AITL cases, RHOA, TET2, IDH2, 
PLCG1 and DNMT3A were mutated in 35.1% (20/57), 
29.8% (17/57), 14.03% (8/57), 14.03% (8/57) and 8.8% 
(5/57) of the cases, respectively (Figure 2).
Conversely, in PTCL-NOS, TET2, PLCG1, RHOA, 
IDH2 and DNMT3A were mutated in 14.6% (6/41), 14.6% 
(6/41), 7.3% (3/41), 7.3% (3/41), and 4.9% (2/41) of the 
cases, respectively (Figure 2).
Only the expression of mutations in the RHOA 
gene differed between AITL and PTCL-NOS tumors (p = 
0.001) (Supplementary Table 4).
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The G17V change was the only mutation found 
in the RHOA gene, the alteration occurring in the GTP-
binding domain of RHOA predicted to have a damaging 
function (Supplementary Figure 2). TET2 was the only 
gene in which two simultaneous mutations were found 
in two independent cases each, both of them being AITL 
cases (cases 31 and 39). Most of these gene alterations 
were missense mutations (52% of cases), mutations leading 
to premature stop codons (52% of cases) or alterations in 
splice sites (8.7%). The same TET2-L1340R mutation 
was found in two cases. This alteration is predicted to 
have a damaging function and has also been described 
in at least two previous independent studies [8, 9]. 
The profile of mutations in the DNMT3A gene was 
similar, with 71.4% missense mutations, 14.2% mutations 
leading to premature stop codons and 14.2% of alterations 
in splice sites. Again, only two (R736C and V690D) of 
the seven mutations (28.6%) found had been previously 
described [8, 10].
Mutations in the IDH2 gene were all missense 
mutations affecting the same codon, although they give 
rise to different substitutions (four R172S, four R172G 
and three R172K). All these mutations have been predicted 
to have a damaging function.
We had previously used qPCR for the PLCG1 gene 
analysis to identify 10/98 cases (10.2%) in this series 
(represented in black in the cluster) with the PLCG1-
S345F mutation (6 AITL and 4 PTCL-NOS) [11]. We have 
identified four other mutations, three of them missense 
mutations (Y509H; G1248A and E589V) and one of them 
an alteration in the 3`UTR region. None of them has been 
previously described. 
In the whole series, mutations in the RHOA gene 
were related to the presence of mutations in the IDH2, 
TET2 and DNMT3A genes (p < 0.005; p < 0.043; and p < 
0.029, respectively). No associations were found between 
any of the other genes. One of the cases with two double 
TET2 mutations also had a DNMT3A mutation, while none 
of these cases showed alterations in the RHOA gene. 
The variant allele frequency was higher for TET2 
mutations (median, 25.22%; range, 5–64 alleles per 
case) than for RHOA mutations (median, 12.65%; range 
5–34 alleles per case). There were 14 cases with RHOA 
mutations without TET2 mutations. Six of these cases had 
IDH2 mutations, one had a DNMT3A gene mutation and 
another had a mutation in both the IDH2 and DNMT3A 
genes. Only two of the cases with both the RHOA and 
IDH2 mutations showed a greater than 10% variant allele 
frequency for the two genes (cases 45 and 48). Six further 
cases showed no other change in any of these epigenetic-
related genes, four of which had a variant allele frequency 
greater than 10% (Supplementary Table 3).
In the AITL subgroup of tumors, the relationship 
between mutations in the RHOA gene with mutations in 
both IDH2 and DNMT3A (p < 0.005 and p = 0.0028) 
was maintained, while the relationship with mutations 
in the TET2 gene was lost. By contrast, in the PTCL-
NOS subgroup of tumors, mutations in the RHOA gene 
were associated with IDH2 (p < 0.005) and PLCG1 (p 
= 0.008) gene mutations. A strong positive relationship 
was also found between IDH2 and PLCG1 (p = 0.008). 
Interestingly, 42.1% (24/57) of AITL cases did not show 
any of these studied mutations (Figure 1).
No correlations were found between any individual 
mutation or mutational combination with any of the 
analyzed clinical parameters (Supplementary Tables 5–9). 
Correlations between the presence of TFH 
markers and mutations in selected genes
In the whole series, the expression of PD-1 was 
significantly positively correlated with the presence 
of mutations in the TET2 (p = 0.044) and PLCG1 (p = 
0.034) genes. CXCL13 was positively correlated with 
the presence of RHOA mutations (p = 0.002). CD10 was 
correlated with the presence of mutations in the PLCG1 
(p = 0.05) and RHOA (p < 0.001) genes (Supplementary 
Table 10). In the AITL subgroup of tumors the correlations 
between CXCL13 expression and RHOA mutations (p = 
0.001), and between CD10 expression and PLCG1 (p 
= 0.027) and RHOA (p = 0.003) gene mutations were 
maintained. Moreover, a positive association was found 
between the expression of CD10 and the occurrence of 
mutations in the TET2 gene (p = 0.010).
A trend between the TFH-1 group and RHOA gene 
mutations was found (p = 0.068) while no correlations 
were found regarding TFH-2 group. Moreover, the presence 
of three or more TFH markers was related to the presence of 
RHOA gene mutations (p = 0.004).
The presence of double immunohistochemical 
expression of BCL-6/PD-1 was positively correlated with 
the presence of mutations in the RHOA (p = 0.004), IDH2 
(p = 0.036) and PLCG1 (p = 0.009) genes (Supplementary 
Table 10). 
DISCUSSION
In the present series, and in accordance with other 
published reports [8, 12–14], the presence of TFH markers 
was broadly associated with AITL morphology. All TFH 
markers tended to cluster together, and mutations in the 
five genes studied also clustered together, occurring 
at a higher frequency in the AITL subgroup of tumors. 
However, a subgroup of PTCL-NOS showing mutations 
in these genes as well as a TFH phenotype could also 
be identified. Additionally, some AITL cases lack TFH 
markers or the distinctive mutational events. Thus, a grey 
area can be identified between a cluster of AITL cases with 
typical morphology, multiple TFH markers and presence of 
mutated genes with PTCL-NOS without any TFH marker or 
mutated gene. We have looked for clinical correlations that 
could help to identify thresholds or case clusters, but failed 
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Figure 1: Representative association between mutations of selected genes and TFH markers in n-PTCL according to 
morphology. Dark grey: AITL; Light grey with stripes: PTCL-NOS; Dark blue: TFH-phenotype; White: wild-type/no expression; Purple: 
TFH > 10%; Fuchsia: TFH > 50%; Light grey: no data.
Figure 2: Representative association between mutations of selected genes and cases in n-PTCL according to presence/
absence of TFH-phenotype. Dark blue: TFH-phenotype; White: wild-type/no expression; Purple: TFH > 10%; Fuchsia: TFH > 50%; Dark 
orange: 0–1 markers to 50%; Orange: 2–5 markers to 50%; Light grey: no data.
Oncotarget16128www.oncotarget.com
to identify any, although this could be due to the relatively 
small number of cases considered here.
In the present series, CXCL13, PD-1, BCL-6, ICOS 
and CD10 were the most frequently positive markers, 
occurring in 72.94%, 71.42%, 64.63%, 50.63% and 
10.36% of cases, respectively. ICOS expression in this 
subgroup of patients has not been thoroughly studied. 
Most studies indicate that CXCL13 is the most frequently 
expressed gene in AITL and PTCL-NOS samples. Major 
differences arise from the low frequency of CD10-
positive cases found in this study, which could be due to 
the antibody used or the threshold applied. The level of 
expression of TFH markers in the PTCL-NOS subgroup 
of tumors is slightly higher than previously described, 
ranging from 11% to 61% across different series [4, 
15–22]. This discrepancy could be due to an enrichment 
of PTCL-NOS cases with AITL-like morphology in the 
present series. 27.3% of the n-PTCL cases in this series 
exhibited four of the five markers analyzed. Only 7% of 
AITL cases showed none of the markers, while 43.9% of 
the PTCL-NOS showed at least two of them. 
It is of particular note that BCL-6 was the main 
marker differentially expressed between AITL and PTL-
NOS cases. This relationship was maintained when 
double PD1/BCL-6 expressers were analyzed (p = 0.038). 
Miyoshi et al. [18] reported a relationship between the 
expression of BCL-6 and AITL morphology. BCL-6 has 
been described as the master regulator of TFH-cells, and 
can regulate and be regulated by the presence of other 
TFH cell markers [23]. Many TFH cell markers, such as 
CXCL13, PD-1 and CD10, can be seen in other T-cell 
lymphomas such as mycosis fungoides, Sézary syndrome, 
primary cutaneous T-cell lymphoma with TFH-phenotype, 
or in clonal proliferations of small- to medium-sized CD4-
positive T lymphocytes, but BCL-6 is rarely expressed 
[20, 24]. It is not known whether the presence of BCL-6 
is related to the difference in morphology between AITL 
and TFH-PTCL-NOS, or if it has a role in a difference in 
the etiopathogenesis of these two tumor subgroups. 
The percentage of mutated cases in the present 
series was lower than reported in previous studies 
(Supplementary Table 11). Variability of tumor-cell 
content, sequence coverage and efficacy of variant calling 
probably contributed most to the discrepancy with other 
reports, most of which found the highest mutation rate 
to be in the TET2 gene, followed by RHOA. Mutations 
of TET2, IDH2 and DNMT3A usually coexist in AITL 
patients, unlike the case of myeloid neoplasm, in which 
TET2 and IDH2 mutations appear to be mutually 
exclusive. Furthermore, the variant allele frequency 
is higher for TET2 and DNMT3A mutations than for 
RHOA mutations in AITL cases [9]. TET2 and DNMT3A 
mutations are thought to occur at an early stage of 
hematopoietic cell differentiation since they are also found 
in non-malignant hematopoietic cells, non-transformed 
CD20-positive immunoblasts in AITL patients, as well as 
in normal elderly individuals. Based on these observations, 
a multistage developmental pathway for AITL has been 
suggested, in which TET2 and DNMT3A are both early 
events related to enhanced self-renewal, while mutations 
in the RHOA gene, among others, are secondary events 
associated with the malignant transformation of lineage 
commitment [8–10, 25–28]. However, we found no 
relationship between TET2 and DNMT3A mutations, 
although one of the cases with mutations in both genes 
had two different mutations in the TET2 gene, in 
accordance with previous reports. Although the variant 
allele frequencies of the TET2 and DNMT3A genes were 
higher than that of the RHOA gene, we found six RHOA 
gene-mutated cases that had no other mutations in TET2, 
DNMT3A or IDH2. In the present series, all IDH2-mutated 
cases also had RHOA gene mutations that were present in 
the AITL and PTCL-NOS patients. Although most authors 
suggest a close correlation between mutations in IDH2 and 
AITL morphology, only one study has yielded results that 
concur with ours [14]. 
Only mutations in the RHOA gene were 
differentially expressed between AITL and PTCL-NOS 
tumors (p = 0.001). AITL is pathologically characterized 
by marked proliferation of endothelial venules, expanded 
follicular dendritic cell (FDC) meshworks around the 
venules, diffuse polymorphic infiltrates, and the expansion 
of EBV-positive or EBV-negative B-immunoblasts [29]. 
Three histological patterns are recognized, of which 
the most common is absent follicles, although cases 
with depleted or hyperplastic follicles have also been 
described [30]. Our findings concur with those of two 
previous studies showing the association between the 
presence of the RHOA-G17V mutation and a classic AITL 
morphology with expanded dendritic meshwork and TFH 
phenotype [31, 32].
We and other researchers have described a relatively 
high percentage of AITL patients without mutations in 
any of the genes here mentioned. A priori, these results 
suggest that alternative pathogenic events play a role in 
the development of AITL, at least in a subgroup of these 
patients. So, alternative ways of changing the same or 
different genes in these pathways are probably responsible 
for the development of these non-mutated patients. 
TET2 mutation is the only mutated gene known to be 
correlated with aggressive clinical features [22]. However, 
our data do not support this or any other association. 
A close relationship was found between the presence 
of these mutations and a TFH-phenotype in both AITL 
and TFH-phenotype PTCL-NOS patients, suggesting 
the existence of a core of AITL cases carrying both TFH 
phenotype and mutated genes. Nevertheless, the frequency 
of mutated cases was much lower than that of cases with a 
TFH phenotype [23, 33]. No clinical or survival differences 
were found regarding these subgroups. Combinations 
of two, three and four TFH markers showed different 
correlations with mutated genes. RHOA gene mutations 
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were associated with most combinations of TFH-markers. 
PD-1/CD10 as well as double-expresser tumors for PD1 
and BCL-6 proteins were correlated with the presence 
of most mutated genes (RHOA, IDH2 and PLCG1). No 
clinical differences were found in any association between 
gene mutations and TFH-markers. These results make it 
very difficult to recommend which TFH proteins should be 
used to identify n-PTCL with TFH phenotype, but it is clear 
that the use of multiple markers should be accompanied 
by a standardization of the techniques and interpretation 
of results.
Except for the RHOA and IDH2 genes, the number 
and function of mutations in the other genes, especially 
TET2 and DNMT3A, are highly variable. This means that 
they are not very useful in daily clinical practice, although 
they may be of great biological significance, suggesting 
that AITL pathogenesis could arise in some cases from 
the clonal expansion of hematopoietic precursor cells. 
The presence of most of these mutations is not specific to 
AITL or other TFH-PTCL-NOS cases, since they have also 
been found to be mutated in cutaneous T-cell lymphomas, 
Sézary syndrome, T-cell prolymphocytic leukemia, adult 
T-cell leukemia/lymphoma, acute lymphoblastic leukemia, 
T-cell and NK-cell post-transplant lymphoproliferative 
disorders, and in diffuse large B-cell lymphomas [34–44]. 
To the best of our knowledge, the IDH2 gene has not been 
found to be mutated in other subgroups of lymphomas, 
except for exceptional cases of lymphoblastic leukemia 
[45], making it somehow characteristic of these subgroups 
of tumors. Unfortunately, they were present in only 11.2% 
of our cases, compared with the highest reported rate of 
33.3% [28]. Nevertheless, the knowledge of the mutational 
status of n-PTCL samples could be useful as markers for 
guiding future therapy or patient follow-up [46–48]. 
In conclusion, AITL differed from TFH-PTCL-NOS 
cases with respect to morphology, BCL-6 expression and 
RHOA mutation rate, although none of these features had 
clinical implications. In general, the AITL and TFH-PTCL-
NOS subgroups of tumors share morphological features, 
immunophenotype, molecular background and clinical 
behavior. Considering all these features together could 
justify ascribing all these entities to a single category in 
the lymphoma classification [1]. 
MATERIALS AND METHODS
Patient samples
The series included 98 formalin-fixed, paraffin-
embedded (FFPE) n-PTCL cases (57 AITL and 41 
PTCL-NOS). Diagnostic criteria were based on the WHO 
classification [1]. All samples were reviewed by two 
pathologists (SMR-P and MAP) to confirm the diagnoses. 
Patients’ clinical data have been reported in previous 
publications [11, 12, 49–51]. Patient characteristics are 
presented in Supplementary Table 12. Samples and clinical 
data of patients included in the study were provided by 
several Spanish Biobanks. The project was supervised 
by the Ethical Committees of the Hospital Universitario 
Marqués de Valdecilla (Santander) and the Fundación 
Jiménez Díaz (Madrid). 
Tissue microarray construction
 Representative areas from FFPE lymphomas 
were carefully selected from H&E-stained sections. 
Three tissue cores of 1 mm diameter were obtained from 
each specimen. The cores were precisely arrayed into a 
new paraffin block using a tissue microarray (TMA) 
workstation (Beecher Instruments, Silver Spring, MD).
Immunohistochemical studies
TMA sections were stained by the EndVision 
method with a heat-induced antigen-retrieval step for 
BCL-6, ICOS, CD10, PD-1 and CXCL13. Reactive tonsil 
tissue was included as a control. The primary antibodies 
were omitted to provide negative controls (Supplementary 
Table 13). Cases were considered to belong to the TFH-
phenotype subgroup when at least two different markers 
were positive. Sixty-eight of 98 cases had valuable TFH-
phenotype data. Two groups were defined on the basis of 
the percentage of positive cells for each marker (group 1, 
>10%; group 2, >50%). Double immunohistochemistry for 
BCL-6/PD-1 was performed on TMA sections. Only 79 of 
the 98 cases produced valuable data.
Double immunoenzymatic staining 
For paraffin-embedded tissues, an initial automated 
dewaxing and rehydration step followed by heat-induced 
(100° C for 20 min) or enzyme-induced (10 to 15 min, 
Bond Enzyme Pretreatment Kit, Leica Biosystems, 
Wetzlar, Alemania) antigen retrieval was performed. Heat-
induced antigen retrieval was performed using pH 8.8 
ethylenediaminetetraacetic acid (EDTA)-based ready-to-
use solution (Leica Biosystems). Slides were subsequently 
incubated with 3% hydrogen peroxide (5 min), optimally 
diluted primary antibody (15 to 30 min), a postprimary 
blocking reagent (to prevent nonspecific polymer binding) 
(8 min), horseradish peroxidase-labeled polymer (8 min), 
and diaminobenzidine substrate (10 min). All reagents 
were components of the Bond Polymer Refine detection 
system (Leica Biosystems). New adhesive labels needed 
for the second staining procedure were applied to the 
slides. A second immunophosphatase (AP) procedure was 
then performed, omitting the dewaxing, rehydration and 
epitope retrieval steps. The primary antibody was applied 
for 40 min, followed by incubation with postprimary AP 
blocking reagent (20 min) and AP-labeled polymer (30 
min), both of which are components of the Bond Polymer 
AP Red detection system (Leica Biosystems). The AP 
reaction was carried out with the Fast Red substrate 
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included in the Bond Polymer AP Red detection system. 
Hematoxylin counterstaining was performed.
DNA extraction 
We extracted genomic DNA (DNAg) of tumoral 
FFPE samples using a QIAamp® DNA FFPE Tissue kit 
(Qiagen Inc., Valencia, CA, USA) in accordance with 
the manufacturer’s protocol. DNAs were quantified with 
Qubit® (Invitrogen, Carlsbad, CA, USA). The quantity and 
quality of DNAs used in constructing libraries for next-
generation sequencing (NGS) were assessed using the 
KAPA Human Genomic DNA Quantification and QC kit 
(KAPA Biosystems Inc., Roche) and the 7500 Real Time 
System (Applied Biosystems, Foster City, CA, USA) in 
accordance with the manufacturer’s protocol.
Detection of PLCG1 mutation by qPCR 
We used two previously described methods [11, 41] 
two detect the S345F mutation of PLCG1. 
NGS Custom Panel design 
The Ion kit AmpliSeq™ Library kit (Life 
Technologies, Carlsbad, California, USA) panel includes 
48 genes being previously found mutated in T-cell 
lymphomas (Supplementary Table 14) and it was designed 
using AmpliSeq™ Custom Ion panel Designer (Life 
Technologies) (https://www.ampliseq.com/browse.action). 
Library preparation and sequencing 
For targeted sequencing we used 30 ng DNAg 
and the Ion AmpliSeq™ custom panel technology (Life 
Technologies), following the standard protocol. The 
quantification of amplifiable library molecules is critical 
for the efficient use of the Ion Torrent NGS platform; we 
performed the qPCR using the Library Quantitation kit 
(Life Technologies) and the StepOne™ System (Applied 
Biosystems, Foster City, CA, USA) in accordance with 
the manufacturer’s protocol. We then prepared and 
enriched the template DNA by PCR emulsion performed 
on Ion Sphere Particles (ISPs). Libraries were sequenced 
using the Ion Proton™ instrument according to the 
manufacturer’s protocol. 
Bioinformatic analysis 
The reads obtained with the sequencer were 
analyzed using the integrated Torrent Suite system (Life 
Technologies). The sequences were aligned with the 
reference genome NCBI Build 37 (UCSC hg19) using 
TMAP-Ion-Alignment software. The variants were then 
identified by the Torrent Variant Caller algorithm and 
the variants were annotated with the Ion Reporter (Life 
Technologies). Relevant somatic mutations were called 
and filtered by excluding: (i) synonymous SNVs; (ii) 
known variants listed in SNP databases (as described 
above); (iii) variants only present in unidirectional reads; 
(iv) variants occurring in repetitive genomic regions; (v) 
variants with coverage of <30X; (vi) variants with fewer 
than five reads in tumor samples; and (vii) mutations 
with a Variant Allele Frequency (VAF) of <0.05. The 
variants were visually checked using Integrated Genome 
Viewer (IGV v2.3; Broad Institute) to exclude artifacts 
and sequencing errors. The COSMIC (Catalogue of 
Somatic Mutations in Cancer) database was checked to 
identify pathogenetic changes. In addition, the variants 
were analyzed with two mutational functional prediction 
programs (SIFT and Polyphen-2).
Statistical analysis 
To assess associations between categorical variables, 
we used the X2 contingency test with Yates’ correction, or 
Fisher’s exact test, as appropriate. Overall survival (OS) 
was taken as the period between the date of diagnosis and 
the date of death from any cause, or of last contact for 
living patients. Disease-specific OS was calculated as the 
period from date of diagnosis until death from the tumor. 
Kaplan–Meier survival analyses were carried out for OS 
and lymphoma-specific survival, using the log-rank test 
to examine differences between groups. A multivariate 
Cox regression model was also derived. Estimates were 
considered statistically significant for two-tailed values of 
p < 0.05. All analyses were carried out with SPSS v.20.0 
(IBM Corp., Armonk, NY, USA) [51].
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